The Association between Serum Endostatin, Kidney Disease Progression, and Mortality in Patients with Chronic Kidney Disease in the Salford Kidney Study
Pulse · 24.03.2026 · 14 (1) · 31-42
DOI: 10.1159/000551072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulse, online erschienen am 24.03.2026. Verfasst von Johanna Helmersson-Karlqvist und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Patients with chronic kidney disease (CKD) have an increased risk of cardiovascular morbidity. Circulating endostatin is associated with both cardiovascular morbidity and impaired kidney function in the general population, but the utility of endostatin as a prognostic marker for CKD progression and mortality in patients with CKD is not well studied. The aim was to study association between serum endostatin and mortality, and also kidney function decline in a cohort of CKD patients (Salford Kidney Study [SKS]).
Methods
Analyses were performed on baseline and annual follow-up samples from 970 adults in the SKS cohort with CKD stage 3–5. Association with mortality was studied using Cox proportional hazard models adjusted for age, gender, systolic and diastolic blood pressure, smoking status, diabetes mellitus, prior cardiovascular disease, creatinine-based estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio (uPCR). Associations between endostatin and eGFR decline were studied with linear regression analyses. eGFR decline was defined as the percentage difference between baseline eGFR and follow-up eGFR (median follow-up, 6.2 years).
Results
Median age of the cohort was 66 years, with a median eGFR of 30 mL/min/1.73 m2. Multivariate Cox regression models revealed an association between higher endostatin levels and mortality with adjustments for established cardiovascular risk factors (HR: 1.14; CI: 1.02–1.28; p = 0.02) but was attenuated and nonsignificant after adjustments for baseline eGFR and uPCR. Baseline levels of endostatin were associated with eGFR decline but were nonsignificant after adjustments for baseline eGFR and uPCR. Changes of endostatin concentrations during the study were significantly associated with eGFR decline in all models (regression coefficient 0.0023% decrease per month [95% confidence intervals 0.0012–0.0034, p < 0.001]).
Conclusion
The clinical utility of plasma endostatin for risk prediction in CKD patients seems limited. Importantly, longitudinal changes of endostatin were significantly associated with eGFR decline. The clinical relevance of this warrants further studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- Department of Renal Medicine, Salford Royal, Northern Care Alliance NHS Foundation Trust, Salford, UK.
- Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
- Center for Primary Health Care Research, Lund University, Malmö, Sweden.
- Academic Primary Health Care Centre, Stockholm, Sweden.
- School of Health and Social Studies, Dalarna University, Falun, Sweden.
Zitieren
APA
Helmersson-Karlqvist, J., Chinnadurai, R., Wändell, P., Carlsson, A. C., Kalra, P. A., Larsson, A. O., Feldreich, T., Ärnlöv, J., & Ruge, T. (2026). The Association between Serum Endostatin, Kidney Disease Progression, and Mortality in Patients with Chronic Kidney Disease in the Salford Kidney Study. Pulse, 14(1), 31-42. https://doi.org/10.1159/000551072
Vancouver
Helmersson-Karlqvist J, Chinnadurai R, Wändell P, Carlsson AC, Kalra PA, Larsson AO, et al. The Association between Serum Endostatin, Kidney Disease Progression, and Mortality in Patients with Chronic Kidney Disease in the Salford Kidney Study. Pulse. 2026;14(1):31-42. doi:10.1159/000551072
BibTeX
@article{HelmerssonKarlqvist2026,
author = {Helmersson-Karlqvist, Johanna and Chinnadurai, Rajkumar and Wändell, Per and Carlsson, Axel Carl and Kalra, Philip A and Larsson, Anders Olof and Feldreich, Tobias and Ärnlöv, Johan and Ruge, Toralph},
title = {The Association between Serum Endostatin, Kidney Disease Progression, and Mortality in Patients with Chronic Kidney Disease in the Salford Kidney Study},
journal = {Pulse},
year = {2026},
volume = {14},
number = {1},
pages = {31--42},
doi = {10.1159/000551072}
}
EUVIMED